Long-term bevacizumab is safe and effective in managing small bowel angioectasias bleeding refractory to conventional treatments: a case report
- PMID: 38974879
- PMCID: PMC11227363
- DOI: 10.1093/gastro/goae070
Long-term bevacizumab is safe and effective in managing small bowel angioectasias bleeding refractory to conventional treatments: a case report
Conflict of interest statement
None to declare for all authors. Figure 1.Mean Hb levels during the observation period. The grey thinner box corresponds to the lower dose of bevacizumab. Hb = haemoglobin, BVZ = bevacizumab.
Figures
References
-
- Holleran G, Hall B, Zgaga L. et al. The natural history of small bowel angiodysplasia. Scand J Gastroenterol 2016;51:393–9. - PubMed
-
- Lanas A, García-Rodríguez LA, Polo-Tomás M. et al. The changing face of hospitalisation due to gastrointestinal bleeding and perforation. Aliment Pharmacol Ther 2011;33:585–91. - PubMed
-
- Nardone G, Compare D, Martino A. et al. Pharmacological treatment of gastrointestinal bleeding due to angiodysplasias: A position paper of the Italian Society of Gastroenterology (SIGE). Dig Liver Dis 2018;50:542–8. - PubMed
-
- Albitar HAH, Almodallal Y, Papadakis KA. et al. Intravenous bevacizumab reduces transfusion requirements and endoscopic interventions in patients with gastric antral vascular ectasia and small bowel angioectasia. Gastroenterology 2020;158:1162–3.e4. - PubMed
LinkOut - more resources
Full Text Sources
